Serina Therapeutics reported that all eight patients in Cohort 1 had been enrolled and dosed ahead of its guidance for the end of the third quarter of 2026. An independent committee will review safety and tolerability before the company provides a further update.
Simba has more than 30 years of experience in biotech and pharmaceuticals, including executive roles at Maxygen, Systemix, Boehringer Mannheim and Celltech. He has also held roles at Flagship Pioneering and TPG and is a board member at Foghorn Th.
Serina Therapeutics is located at the HudsonAlpha Institute for Biotechnology. Serina Therapeutics, Inc. 601 Genome Way, Suite 2001 Huntsville, Alabama 35806 256.327.9630
Serina Therapeutics’ Privacy Policy describes the information it collects from visitors to its website and how it uses that information. It applies to pages, services, software and capabilities accessible through the website.
Serina Therapeutics says it owns, controls and maintains its website for information and general education. The page sets out terms of use, including acceptance of those terms and the company’s intellectual property rights.
